AUTHOR=Li Juan , Bi De , Zhang Xin , Cao Yunpeng , Lv Kun , Jiang Lan 

TITLE=Network Pharmacology and Inflammatory Microenvironment Strategy Approach to Finding the Potential Target of Siraitia grosvenorii (Luo Han Guo) for Glioblastoma

JOURNAL=Frontiers in Genetics

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.799799

DOI=10.3389/fgene.2021.799799

ISSN=1664-8021

ABSTRACT=<p><bold>Background:</bold> Glioblastoma (GBM) is the most common and aggressive primary intracranial tumor of the central nervous system, and the prognosis of GBM remains a challenge using the standard methods of treatment—TMZ, radiation, and surgical resection. Traditional Chinese medicine (TCM) is a helpful complementary and alternative medicine. However, there are relatively few studies on TCM for GBM.</p><p><bold>Purpose:</bold> We aimed to find the connection between TCM and anti-GBM.</p><p><bold>Study design:</bold> Network pharmacology and inflammatory microenvironment strategy were used to predict <italic>Siraitia grosvenorii</italic> (Luo Han Guo) target for treating glioblastoma.</p><p><bold>Methods:</bold> We mainly used network pharmacology and bioinformatics.</p><p><bold>Results:</bold> CCL5 was significantly highly expressed in GBM with poor prognostics. Uni-cox and randomForest were used to determine that CCL5 was especially a biomarker in GBM. CCL5 was also the target for SG and TMZ. The active ingredient of Luo Han Guo — squalene and CCL5 —showed high binding efficiency. CCL5, a chemotactic ligand, was enriched and positively correlated in eosinophils. CCL5 was also the target of Luo Han Guo, and its effective active integrate compound –— squalene — might act on CCL5.</p><p><bold>Conclusion:</bold> SG might be a new complementary therapy of the same medicine and food, working on the target CCL5 and playing an anti-GBM effect. CCL5 might affect the immune microenvironment of GBM.</p>